4th ADC Linker & Conjugation Summit
Linking Chemistry to Clinical Success Through Better ADC Design
- When? July 28-30, 2026
- Where? Boston, MA
ADC development is evolving fast, with developers pushing beyond traditional cytotoxins into dual‑payload constructs, high‑DAR species, degrader–antibody conjugates, and next‑generation modalities. This surge in innovation is placing new pressure on linker architecture and conjugation chemistry to improve stability, reduce off‑target toxicity, and maintain manufacturability at scale.
This year introduces expanded workshops and interactive debates, including new sessions examining how to more effectively connect linker chemistry to translational outcomes and how to redesign payloads using emerging linker technologies. The 2026 meeting also welcomes 17 new speakers from 13 new companies, offering fresh insight into the rapidly diversifying toolkit available for ADC design.
For scientists working at the core of ADC chemistry, this summit provides a rare opportunity to benchmark strategies, challenge assumptions, and contribute to the next decade of linker and conjugation innovation.
View the full program and explore the 2026 agenda
Download the event guide here: https://ter.li/7pj7r6